A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

The updated standard replaces three previous guidelines and reflects the latest thinking on tackling obesity through the ...

Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

People using weight loss medication have been told it's not a "quick fix" with many at risk of regaining their lost weight.

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

People using weight loss medication have been warned it is not a "quick fix" with many at risk of regaining their lost weight ...

Patients ending obesity medication or finishing a weight management programme should be offered support to help keep the ...

Facebook posts reveal more GI side effects from semaglutide drugs like Ozempic than Mounjaro, offering new insights into ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Doctors at ZAVA warned that these summer staples can cause your blood sugar levels to crash and dehydrate you. This effect ...

Health chiefs have raised concerns about patients regaining weight after stopping popular weight-loss drugs such as Wegovy ...